TICKERNERD
Menu
IXHLIXHLHealthcare · Drug Manufacturers - Specialty & Generic

IXHL Stock Forecast: Incannex Healthcare, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$2.71
+3.44% on the day

The 1 Wall Street analysts covering Incannex Healthcare, Inc. hold a median 12-month price target of $19 — +597.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$32.9M
Ticker Nerd rank
24/ 100
Median analyst target
$19
Analysts covering
1
Revenue$0.0
Operating income−$4.0M
Net income−$3.9M
Free cash flow−$2.5M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.8%
1M
−14.0%
YTD
−74.8%
1Y
−74.8%
From 52W high
−81.1%
From 52W low
+5.9%
$3
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IXHL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Incannex Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
24/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
84
Issuance
60
Growth
59
Quality
50
Accruals
44
Revisions
26
Volatility
15
Value
9
Momentum
6

Size (84): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IXHL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IXHL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26IXHLHigh $20Median $19Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $18Median $19High $20

The green dot is the last close — the median target sits +597.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026Alliance Global PartnersInitiatesBuy$18
8 June 2026Alliance Global PartnersInitiatesBuy—
8 Dec 2022MizuhoMaintainsNeutral—
16 Nov 2022KeybancDowngradeSector Weight—
3 Nov 2022BarclaysMaintainsOverweight—
3 Nov 2022MizuhoDowngradeNeutral—
3 Nov 2022Raymond JamesMaintainsOutperform—
3 Nov 2022RBC CapitalMaintainsOutperform—
3 Nov 2022Truist SecuritiesDowngradeHold—
24 Oct 2022KeybancMaintainsOverweight—
24 Oct 2022Morgan StanleyMaintainsEqual-Weight—
24 Oct 2022RBC CapitalMaintainsOutperform—
24 Oct 2022Truist SecuritiesMaintainsBuy—
21 Oct 2022NeedhamDowngradeHold—
17 Oct 2022MizuhoMaintainsBuy—
11 Oct 2022Canaccord GenuityInitiatesBuy—
23 Sept 2022BTIGInitiatesNeutral—
4 Aug 2022MizuhoMaintainsBuy—
4 Aug 2022Morgan StanleyMaintainsEqual-Weight—
4 Aug 2022NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IXHL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IXHL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Incannex Healthcare, Inc. returned −74.8% against +13.6% for the S&P 500, dividends included.

IXHL vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26IXHLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IXHL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Incannex Healthcare, Inc. (IXHL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
0.5×

Cheaper than 83% of US stocks

EV / EBITDA
1.9×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−47.8%

Higher than 22% of US stocks

Return on assets
−24.6%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Incannex Healthcare, Inc. (IXHL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Incannex Healthcare, Inc. has a market value of $32.9M and an enterprise value of −$34.7M.

  • Shares outstanding: 13.7M.

  • Trailing P/E: −0.1×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Incannex Healthcare, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

IXHL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
IXHLIncannex Healthcare, Inc.$32.9M24
RMTIRockwell Medical, Inc.$28.9M56
SCYXSCYNEXIS, Inc.$39.2M41
CPHIChina Pharma Holdings, Inc.$26.7M41
SHPHShuttle Pharmaceuticals Holdings, Inc.$25.0M18
ZYBTZhengye Biotechnology Holding Ltd.$42.2M49
OPTHOptimi Health Corp.$23.6M—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Incannex Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IXHL news & analysis

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26

Newsfile Corp · 1 Oct 2026positive

Stonegate Capital Partners updated its coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) following the company's FY26 update, noting that the IHL-42X program has moved from DReAMzz preparation into active clinical execution. The coverage highlights that first-patient dosing is underway and that the company's balance sheet provides at least 12 months of runway for planned operations.

Why it matters — A watcher would find this significant because it marks IHL-42X's progression into active clinical execution with funding in place, and an updated analyst coverage report signals fresh attention on the company's near-term prospects.

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

GlobeNewsWire · 9 Sept 2026positive

Incannex Healthcare provided a corporate update announcing that patient dosing has commenced in its DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea, that a U.S. composition and methods of treatment patent covering IHL-42X was granted with a baseline expiry in 2040, and that the company holds approximately $70 million in cash with no debt, including more than A$11.2 million in non-dilutive capital received during 2026.

Why it matters — A IXHL watcher would care because the update advances the company's lead clinical program, extends its intellectual property protection for IHL-42X into 2040, and indicates a strong cash position that supports ongoing operations without debt.

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

GlobeNewsWire · 25 Aug 2026positive

Incannex announced that the first patient has been dosed in the DReAMzz Phase 2 study of IHL-42X. This milestone follows positive Phase 2 RePOSA results showing reductions in apnea-hypopnea index of up to 83% and FDA Fast Track designation.

Why it matters — This clinical milestone advances IHL-42X's development and builds on prior positive Phase 2 data and FDA Fast Track status, which could be significant for IXHL watchers tracking the program's progress.

FAQ

Frequently asked questions about IXHL stock

What is the IXHL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Incannex Healthcare, Inc. have a median 12-month price target of $19, with estimates ranging from $18 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IXHL stock a buy right now?

Of the 1 analysts covering Incannex Healthcare, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Incannex Healthcare, Inc. 24 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IXHL?

As at 28 Oct 2026, Incannex Healthcare, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).

Will IXHL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +597.7% from the last close, and Ticker Nerd's factor model ranks Incannex Healthcare, Inc. 24 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IXHL stock forecast for 2030?

No analyst covering Incannex Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IXHL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $20 over the next 12 months.

How has IXHL stock performed over the past year?

Incannex Healthcare, Inc. returned -74.8% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Incannex Healthcare, Inc. do?

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral combination medicines and psychedelic-based therapies for chronic conditions with limited treatment options.

What is the latest news on IXHL?

The most recent item we track (Newsfile Corp, 1 Oct 2026): "Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26". Stonegate Capital Partners updated its coverage on Incannex Healthcare Inc. (NASDAQ: IXHL) following the company's FY26 update, noting that the IHL-42X program has moved from DReAMzz preparation into active clinical execution. The coverage highlights that first-patient dosing is underway and that the company's balance sheet provides at least 12 months of runway for planned operations.

Company

About Incannex Healthcare, Inc.

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company focused on developing oral combination medicines and psychedelic-based therapies for chronic conditions with limited treatment options. Incannex Healthcare Inc. is currently advancing programs in obstructive sleep apnea, generalized anxiety disorder, rheumatoid arthritis, and inflammatory disorders through its research and development of cannabinoid and psychedelic pharmaceutical products. Its pipeline includes fixed-dose and synthetic oral treatments designed to target underlying biological pathways and support clinical development across sleep medicine, mental health, and inflammation. Based in Sydney, Australia, Incannex Healthcare Inc. operates as a science-led developer of novel therapeutics aimed at addressing significant unmet medical needs in modern healthcare.

CEO Mr. Joel Bradley Latham · 12 employees · Australia · https://www.incannex.com